ATAI

AtaiBeckley Inc. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. AtaiBeckley Inc. is a clinical-stage biotechnology company formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited. The company focuses on developing psychedelic and non-psychedelic therapies for mental health disorders. In December 2025, the company completed a redomiciliation transaction, moving its corporate domicile from the Netherlands to Delaware, USA.

Key Financial Metrics

Note: Revenue is derived primarily from licensing and R&D services via the Nualtis subsidiary, not from core product sales.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 39% ($0.60 million) year-over-year, driven by a 44% drop in research and development services revenue ($0.80 million vs. $1.35 million).
• Increased Operating Expenses: Total operating expenses rose 45% to $31.86 million.
  • R&D Expenses: Increased 54% to $17.41 million, primarily due to higher direct costs for programs BPL-003, VLS-01, and EMP-01, and increased personnel costs following the Beckley Psytech integration.
  • G&A Expenses: Increased 36% to $14.44 million, driven by higher legal, intellectual property, and professional service fees.
• Net Loss Increase: Net loss attributable to stockholders increased 13% to $29.78 million. This was partially offset by a significant improvement in "Other income (expense), net," which swung from a $5.94 million loss in Q1 2025 to a $1.12 million gain in Q1 2026.
• Fair Value Volatility: The company recognized a $6.0 million gain on pre-funded warrant liabilities and a $1.6 million gain on securities, offset by a $2.0 million unrealized loss on digital assets (Bitcoin) and a $5.0 million loss on its COMPASS Pathways investment.
• Cash Position: Cash and cash equivalents decreased by approximately $42.2 million during the quarter due to operating losses and net investing outflows of $21.7 million (primarily purchases of securities).

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash, cash equivalents, and short-term securities ($209.9 million combined) are sufficient to fund operations for at least the next 12 months and potentially into 2029 based on current plans.
• Pipeline Progress:
  • BPL-003: On track to initiate Phase 3 program in Q2 2026 for treatment-resistant depression (TRD).
  • VLS-01: Phase 2 Elumina study progressing; topline results expected in Q4 2026.
  • EMP-01: Phase 2a results showed clinically meaningful improvements for social anxiety disorder.
• Capital Resources: The company entered into an "at-the-market" (ATM) sales agreement with Jefferies LLC in March 2026 to facilitate future equity sales. No sales have occurred under this agreement to date.
• Risks: The company is a clinical-stage entity with no approved products and expects to incur losses for the foreseeable future. Key risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, the need for additional capital, and the volatility of digital asset and equity investment holdings.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $209.9 million liquidity position against the projected burn rate of ~$30 million per quarter.
• Investment Volatility: Assess the impact of the $5.0 million unrealized loss on the COMPASS Pathways investment and the $2.0 million loss on Bitcoin holdings on future earnings volatility.
• Revenue Concentration: Note that revenue is entirely dependent on the Nualtis subsidiary's licensing and service contracts, not core drug sales.
• Pre-Funded Warrants: Review the $38.4 million liability associated with pre-funded warrants and the potential for future dilution upon exercise.
• Regulatory Milestones: Monitor the Q2 2026 initiation of the BPL-003 Phase 3 trials and Q4 2026 topline data for VLS-01 as critical value drivers.